Oxygenta Pharmaceutical Ltd Financial Ratios
OXYGENTAPH · Healthcare · Current price ₹46.6
P/E ratio
-14.7x
P/B ratio
-4.7x
ROE
41.2%
ROCE
-26.0%
Debt / Equity
—
Dividend yield
0.0%
Ratio reference
| Ratio | Value | What it means |
|---|---|---|
| P/E | -14.7x | Price paid per ₹1 of annual earnings — lower is cheaper (context-dependent). |
| P/B | -4.7x | Price relative to book value — <1 can signal deep value or trouble. |
| ROE | 41.2% | Return on equity — how much profit the company earns on shareholder capital. |
| ROCE | -26.0% | Return on capital employed — efficiency including debt. >15% is strong. |
| D/E | — | Leverage — higher means more debt-funded, riskier in downturns. |
Model it yourself — PEG Ratio Calculator
Opens pre-filled with Oxygenta Pharmaceutical Ltd's latest numbers.
Oxygenta Pharmaceutical Ltd profitability
Oxygenta Pharmaceutical Ltd generates a return on equity of 41.2% and a return on capital employed of -26.0%. An ROE consistently above 15% usually points to a quality business with a durable advantage; below 10% suggests weak profitability or a capital-heavy model.
Leverage & valuation
With a debt-to-equity of n/a and a P/E of -14.7x, Oxygenta Pharmaceutical Ltd is conservatively financed. Our overall business-quality score for the company is 5.8 / 10.
Understand the ratios
More on Oxygenta Pharmaceutical Ltd
DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.